Strikingly, etokimab, an anti‐IL‐33‐humanised monoclonal antibody, has undergone a randomised phase 2a clinical trial in the treatment of patients with moderate‐to‐severe AD and has shown promising efficacy.88 The gene discussed is IL33; the disease is Alzheimer disease.